<DOC>
	<DOCNO>NCT02787798</DOCNO>
	<brief_summary>The hyperactivation sympathetic nervous system feature heart failure determinant disease progression risk sudden cardiac death . This research project aim study , drug use condition provide summary product characteristic base European marketing authorization ( indication dosage ) , effect Entresto® activity sympathic nervous system use reference method , microneurographic record sympathetic activity muscle destiny ( MSNA ) . This study try determine double inhibition AT1 receptor neprilysin activity result lower sympathic nervous system burst rate versus single AT1 receptor inhibition use angiotensin-converting-enzyme inhibitor AT1 receptor angiotensin II inhibitor .</brief_summary>
	<brief_title>Evaluation Entresto Effect Sympathic Nervous System Patient With Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensinogen</mesh_term>
	<mesh_term>Angiotensin II</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Men woman 18 year old old heart failure symptomatic leave ventricular systolic dysfunction ( left ventricular ejection fraction ≤ 40 % ) : Functional class New York Heart Association II least 2 hospitalization cardiac decompensation year N terminal pro braintype natriuretic peptide ≥300 pg/ml ( braintype natriuretic peptide ≥100 pg/ml ) usage intravenous diuretic , Functional class New York Heart Association IIIIV , Insufficiently control alternative drugfree therapy ( surgery , cardiac resynchronization ... ) well manage drug therapy : angiotensinconvertingenzyme inhibitor , AT1 receptor angiotensin II inhibitor diuretic beta blocker . Treated maximum dosage AT1 receptor angiotensin II inhibitor angiotensinconvertingenzyme inhibitor New York Heart Association II patient 50 % recommend dose New York Heart Association IIIIV patient New York Heart Association II patient clinical manifestation restrict use maximum dosage , like orthostatic hypotension . Patient member home social security scheme Patient receive direct renin inhibitor like aliskiren Patient receive statin Patient receive phosphodiesterase V inhibitor Patient receive potassiumsparing drug Patient medical history angioedema previous treatment angiotensinconvertingenzyme inhibitor AT1 receptor angiotensin II inhibitor Hypersensitivity component Entresto® Adult protect law Severe renal impairment ( DFGe &lt; 30 ml/min/1,73 m2 ) Severe hepatic impairment , cirrhosis cholestasis ( ChildPugh C class ) Patient receive anticoagulant therapy suffer know hemostatic trouble Patient participate another biomedical research active exclusion period Pregnancy Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Nervous System</keyword>
	<keyword>Cardiac disease</keyword>
</DOC>